Leif R. Nelson
New technologies delivered to your inbox Subscribe
2015-347 – Mayo Clinic has developed compositions and methods for detecting soluble PD-L1
2013-237 – Bim is a biomarker for PD-1 and PD-L1 therapies.
Methods of Treating Cancer by Using PD1 and PD-L1 inhibitors by Using Soluble PD-L1 Levels as a Biomarker
2008-042 – Mayo Clinic has patent rights claiming methods of using PD1 or PD-L1 antibodies to treat cancer by using soluble PD-L1 levels in the serum as a biomarker.
2004-239 – Mayo Clinic has patent rights claiming the use of PD1 and PD-L1 antibodies to treat cancer. The patent rights also include diagnostic and prognostic claims.
2002-064 – Mayo Clinic has patent rights broadly claiming the use of PD-L1 antibodies to treat cancer.
1999-098 – Mayo Clinic has patent rights broadly claiming PD-L1 antibodies along with other PD-L1 related fundamental patent claims.
2014-207 – Mayo Clinic has discovered a therapeutic pathway to target PD-L1 (a.k.a. B7-H1) positive tumors. Inhibition of DNA-PKcs function restores the sensitivity of PD-L1 positive tumors to chemotherapy by two fold.
2011-059 – This web or CD-ROM based electromyography (EMG) training tool consists of an interactive, case-based program that assists trainees in learning the application of electrodiagnostic studies and interpretation of findings.
Aquaporin-4-Binding Autoantibodies in Patients with Neuromyelitis Optica Impair Glutamate Transport by Down-Regulating EAAT2
2008-303 – Materials and Methods for Treating Neuromyelitis Optics (NMO) Methods for treating NMO are claimed including the use of glulamate receptor antagonists and/or compounds that inhibit complement.
2002-039 – Technology Description T cell-mediated immune responses are often harmful in transplant patients and patients with autoimmune disease. Currents treatments to suppress T cell-mediated immune responses include a number of immunosuppressive and anti-inflammatory therapies. A novel means of suppressing this immune response has been developed that utilizes mutant forms of a protein normally... Read More
1998-066 – The Mayo Clinic is developing and testing a synbiotic (composition of synergistic probiotic organisms and a prebiotic) for clinical indications (Croh'n’s, IBD, immunocompromised patients, patients undrgoing chemo or radiation therapy, patients infected with antibiotic resistant organisms. THe synbiotic has proven to be very effective in several animal trials including animals that were... Read More